Stojkovska Anisija, Rus Prelog Polona, Kokalj Palandacic Anja
University Psychiatric Clinic Ljubljana, Slovenia.
Faculty of Medicine, University of Ljubljana, Slovenia.
J Int Med Res. 2025 Jul;53(7):3000605251349393. doi: 10.1177/03000605251349393. Epub 2025 Jul 12.
Semaglutide is a glucagon-like peptide-1 receptor agonist used in the treatment of type 2 diabetes mellitus and management of obesity. Associations of glucagon-like peptide-1 receptor agonist use with psychiatric adverse events and suicidal behavior have been reported. A man in his late 70s with type 2 diabetes and no history of psychiatric illness or cognitive deficits was admitted to our clinic after his first suicide attempt involving the impulsive ingestion of brush cleaner liquid. A month before his presentation, he reported restlessness and depressive mood without any apparent trigger. This period was consistent with the time of semaglutide introduction. His psychiatric symptoms improved after semaglutide discontinuation. This case report highlights the importance of regular monitoring of depression and anxiety symptoms and the possibility of suicidal ideation in individuals with type 2 diabetes treated with semaglutide. This may enable early detection and prevention of serious psychiatric adverse events.
司美格鲁肽是一种胰高血糖素样肽-1受体激动剂，用于治疗2型糖尿病和管理肥胖症。已有报道称使用胰高血糖素样肽-1受体激动剂与精神科不良事件和自杀行为有关。一名70多岁的男性患有2型糖尿病，无精神疾病或认知缺陷病史，在首次自杀未遂（冲动摄入刷洗剂液体）后入住我们的诊所。在他就诊前一个月，他报告出现烦躁不安和抑郁情绪，无明显诱因。这段时间与开始使用司美格鲁肽的时间一致。停用司美格鲁肽后，他的精神症状有所改善。本病例报告强调了对使用司美格鲁肽治疗的2型糖尿病患者定期监测抑郁和焦虑症状以及自杀意念可能性的重要性。这可能有助于早期发现和预防严重的精神科不良事件。
